BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27409178)

  • 1. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
    Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
    Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
    Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts.
    Thimsen V; Hölsken A; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Losa M; Jones DT; Buslei R
    Sci Rep; 2016 Jul; 6():29731. PubMed ID: 27431859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rathke's cleft cysts with significant squamous metaplasia--high risk of postoperative deterioration and close origins to craniopharyngioma.
    Ogawa Y; Watanabe M; Tominaga T
    Acta Neurochir (Wien); 2013 Jun; 155(6):1069-75. PubMed ID: 23371400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late development of craniopharyngioma following surgery for Rathke's cleft cyst.
    Park YS; Ahn JY; Kim DS; Kim TS; Kim SH
    Clin Neuropathol; 2009; 28(3):177-81. PubMed ID: 19537134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
    Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
    Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
    Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
    Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.
    Mukada N; Tosaka M; Matsumura N; Yamaguchi R; Aihara M; Isoda K; Higuchi T; Tsushima Y; Yokoo H; Yoshimoto Y
    Sci Rep; 2021 Jan; 11(1):126. PubMed ID: 33420213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological study of Rathke's cleft cysts.
    Ikeda H; Yoshimoto T
    Clin Neuropathol; 2002; 21(2):82-91. PubMed ID: 12005257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E mutation is a useful marker for differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma.
    Kim JH; Paulus W; Heim S
    J Neurooncol; 2015 May; 123(1):189-91. PubMed ID: 25820214
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of Rathke's cleft cyst based on cyst location with a primary focus on recurrence after resection.
    Chotai S; Liu Y; Pan J; Qi S
    J Neurosurg; 2015 Jun; 122(6):1380-9. PubMed ID: 25679272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral Rathke's Cleft Cyst Remnants Within Craniopharyngioma, Pituitary Adenoma, Suprasellar Dermoid, and Epidermoid Cysts: A Ubiquitous Signature of Ectodermal Lineage or a Transitional Entity?
    Manjila S; Asmar NE; Vidalis BM; Alonso F; Singh G; Vadamalai K; Cohen ML; Bambakidis NC; Arafah BM; Selman WR
    Neurosurgery; 2019 Aug; 85(2):180-188. PubMed ID: 30010935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology and pathogenesis of craniopharyngiomas.
    Larkin SJ; Ansorge O
    Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.